FR2981650B1 - Analogues de nucleosides pour le traitement d'une infection virale et methode d'evaluation de la sensibilite audit traitement - Google Patents

Analogues de nucleosides pour le traitement d'une infection virale et methode d'evaluation de la sensibilite audit traitement

Info

Publication number
FR2981650B1
FR2981650B1 FR1159622A FR1159622A FR2981650B1 FR 2981650 B1 FR2981650 B1 FR 2981650B1 FR 1159622 A FR1159622 A FR 1159622A FR 1159622 A FR1159622 A FR 1159622A FR 2981650 B1 FR2981650 B1 FR 2981650B1
Authority
FR
France
Prior art keywords
treatment
viral infection
nucleoside analogues
evaluating sensitivity
evaluating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1159622A
Other languages
English (en)
French (fr)
Other versions
FR2981650A1 (fr
Inventor
Vincent Calvez
Anne Genevieve Marcelin
Cathia Soulie
Quelquejeu Melanie Etheve
Matthieu Sollogoub
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Pierre et Marie Curie
Original Assignee
Universite Pierre et Marie Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Pierre et Marie Curie filed Critical Universite Pierre et Marie Curie
Priority to FR1159622A priority Critical patent/FR2981650B1/fr
Priority to CA2849969A priority patent/CA2849969A1/fr
Priority to EP12790609.7A priority patent/EP2771344B1/fr
Priority to PCT/FR2012/052433 priority patent/WO2013060980A1/fr
Priority to US14/354,044 priority patent/US9181294B2/en
Priority to JP2014537693A priority patent/JP2014532636A/ja
Publication of FR2981650A1 publication Critical patent/FR2981650A1/fr
Application granted granted Critical
Publication of FR2981650B1 publication Critical patent/FR2981650B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR1159622A 2011-10-24 2011-10-24 Analogues de nucleosides pour le traitement d'une infection virale et methode d'evaluation de la sensibilite audit traitement Expired - Fee Related FR2981650B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR1159622A FR2981650B1 (fr) 2011-10-24 2011-10-24 Analogues de nucleosides pour le traitement d'une infection virale et methode d'evaluation de la sensibilite audit traitement
CA2849969A CA2849969A1 (fr) 2011-10-24 2012-10-23 Analogues de nucleosides pour le traitement d'une infection virale, et methode d'evaluation de la sensibilite audit traitement
EP12790609.7A EP2771344B1 (fr) 2011-10-24 2012-10-23 Analogues de nucleosides pour le traitement d'une infection virale, et methode d'evaluation de la sensibilite audit traitement
PCT/FR2012/052433 WO2013060980A1 (fr) 2011-10-24 2012-10-23 Analogues de nucleosides pour le traitement d'une infection virale, et methode d'evaluation de la sensibilite audit traitement
US14/354,044 US9181294B2 (en) 2011-10-24 2012-10-23 Nucleoside analogues for the treatment of a viral infection, and method for evaluating the sensitivity to said treatment
JP2014537693A JP2014532636A (ja) 2011-10-24 2012-10-23 ウイルス感染の処置のためのヌクレオシドアナログおよび該処置に対する感受性を評価するための方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1159622A FR2981650B1 (fr) 2011-10-24 2011-10-24 Analogues de nucleosides pour le traitement d'une infection virale et methode d'evaluation de la sensibilite audit traitement

Publications (2)

Publication Number Publication Date
FR2981650A1 FR2981650A1 (fr) 2013-04-26
FR2981650B1 true FR2981650B1 (fr) 2013-12-27

Family

ID=47221470

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1159622A Expired - Fee Related FR2981650B1 (fr) 2011-10-24 2011-10-24 Analogues de nucleosides pour le traitement d'une infection virale et methode d'evaluation de la sensibilite audit traitement

Country Status (6)

Country Link
US (1) US9181294B2 (enExample)
EP (1) EP2771344B1 (enExample)
JP (1) JP2014532636A (enExample)
CA (1) CA2849969A1 (enExample)
FR (1) FR2981650B1 (enExample)
WO (1) WO2013060980A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016057866A1 (en) * 2014-10-09 2016-04-14 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
US11839623B2 (en) 2018-01-12 2023-12-12 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof
US11458136B2 (en) 2018-04-09 2022-10-04 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4924624A (en) * 1987-10-22 1990-05-15 Temple University-Of The Commonwealth System Of Higher Education 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
GB8921469D0 (en) * 1989-09-22 1989-11-08 Erba Carlo Spa 5'-alkylphosphonylnucleosides as antivirals
PH30703A (en) * 1990-06-21 1997-09-16 Patrick T Prendergast Administering particular compounds against variousparasites, mycoplasmas, other indications and otheer indications and other infections.
US20030008841A1 (en) * 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
SG144146A1 (en) * 2004-03-05 2008-07-29 Cambridge Biotechnology Ltd Adenosine receptor agonists

Also Published As

Publication number Publication date
EP2771344B1 (fr) 2016-04-13
JP2014532636A (ja) 2014-12-08
WO2013060980A1 (fr) 2013-05-02
US9181294B2 (en) 2015-11-10
FR2981650A1 (fr) 2013-04-26
US20140323425A1 (en) 2014-10-30
CA2849969A1 (fr) 2013-05-02
EP2771344A1 (fr) 2014-09-03

Similar Documents

Publication Publication Date Title
EP2731433A4 (en) 5'-SUBSTITUTED NUCLEOSIDE ANALOGA AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES
LT3301193T (lt) Didžiu paremta vaisiaus dnr frakcijos motinos kraujo plazmoje analizė
EP2696681A4 (en) 2'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES
EP2493479A4 (en) METHOD FOR THE TREATMENT OF VIRUS DISEASES
EP2694686A4 (en) COMPOSITION AND METHOD FOR MODIFYING 5-METHYLCYTOSINE (5MC)
EP2393815A4 (en) PURIN NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR THE TREATMENT OF CANCER AND VIRUS INFECTIONS
EP2697242A4 (en) 2'-AZIDO-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES
EP2136633A4 (en) CANCER THERAPY WITH ONCOLYTIC VACCINIAVIRUS
EP2731434A4 (en) 5'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES
EP2909210A4 (en) 2'-DISUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHOD FOR THE USE THEREOF FOR THE TREATMENT OF VIRUS DISEASES
EP2696679A4 (en) 2'-CYAN SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES
EP2619215A4 (en) Azido nucleosides and nucleotide analogs
EP2794627A4 (en) SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGUE THEREOF
EP2773251A4 (en) DISPENSER AND POLLUTION SENSOR
EP2827875A4 (en) SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGUE THEREOF
EP2678675A4 (en) METHOD FOR DETECTING ANEUPLOIDIA IN HUMAN EMBRYOS
EP2707541A4 (en) METHOD FOR THE TREATMENT OF CELLULOSE AND CELLULOSE TREATED IN THIS PROCEDURE
EP2740419A4 (en) TREATMENT INSTRUMENT
EP2658551A4 (en) TREATMENT OF EFFECTS AND OTHER INDICATIONS
EP2582683A4 (en) TREATMENT OF GAS AND HYPERURICEMIA
EP2702075A4 (en) NEUTRALIZING ANTIBODIES TO NIPAH AND HENDRA VIRUSES
EP2443257A4 (en) METHOD FOR DETERMINING THE RESPONSE TO TREATMENT WITH AN IMMUNOMODULATING COMPOSITION
EP2753326A4 (en) METHOD FOR THE TREATMENT OF INTRAPULMONARY INFECTIONS
EP2773342A4 (en) COMPOSITIONS FOR THE TREATMENT OF VIRUS DISEASES
EP2323681A4 (en) METHOD FOR TREATING VIRAL DISEASES

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

ST Notification of lapse

Effective date: 20200914